Drugs / TQB2210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06929195 | May 2025 → Apr 2026 | cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06929195 ↗ |
| Known as | TQB2210 Injection | “Clinical Trial to Evaluate the Tolerance of TQB2210 Injection” NCT06929195 ↗ |
| Action | Inhibit | “It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor.” NCT06929195 ↗ |
| Modality | Monoclonal antibody | “TQB2210 injection is a humanized monoclonal antibody against FGFR2b” NCT06929195 ↗ |
| Route | Intravenous | “Intravenous infusion once of TQB2210 for injection every two weeks” NCT06929195 ↗ |
| Target | FGFR2 | “humanized monoclonal antibody against FGFR2b” NCT06929195 ↗ |